UOC
GNMX

UBS O'Connor’s Aevi Genomic Medicine Inc GNMX Stock Holding History

UBS O'Connor’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$278K – 527
2016
Q2 		$278K Buy
+50,000
New +$263K 0.01% 364

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS O'Connor's GNMX Position: Q3 2016 in Review

UBS O'Connor sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2016, closing a stake of 50,000 shares — an estimated $278K sold.

UBS O'Connor first reported a position in GNMX in Q2 2016 and held it in 1 quarter. The position peaked at $278K in Q2 2016. 68 funds tracked by Wall St. Rank hold GNMX as of Q3 2016.

  • UBS O'Connor reported no remaining Aevi Genomic Medicine Inc position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 50,000 Aevi Genomic Medicine Inc shares in Q3 2016, an estimated $278K.
  • UBS O'Connor first reported a position in Aevi Genomic Medicine Inc in Q2 2016 and held it in 1 quarter.
  • UBS O'Connor's Aevi Genomic Medicine Inc position peaked at $278K in Q2 2016.
  • 68 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.